Celltrion launches biosimilar of AbbVie's Humira in US
Carl Lokko
South Korea's Celltrion (OTC:CONIF) has launched a high-concentration, citrate-free formulated biosimilar of AbbVie's (NYSE:ABBV) Humira in the US.
The biosimilar, which is called Yuflyma, was approved by the FDA in May. Yuflyma's list price is $6,576.50 per month, Celltrion said.
Humira, also known as adalimumab, has been a best-seller for AbbVie for years. The drug, which is used to treat a wide variety of autoimmune disorders, has been facing increased competition from biosimilars, including those launched by Novartis's (NVS) Sandoz unit, Coherus (CHRS), Amgen (AMGN), Fresenius (OTCPK:FSNUF) (OTCPK:FSNUY), Boehringer Ingelheim and Organon (OGN). 
Humira was the world's top-selling drug for ten years in a row, generating sales of $21B for AbbVie in 2021. Biosimilars of the product began to appear on the US market in January 2023.
More on Humira biosimilars:

More AbbVie Humira biosimilars launched (updated)
Organon launches biosimilar of AbbVie's Humira
AbbVieâs global bestseller to face knockoffs starting this week
AbbVieâs global bestseller to face knockoffs starting this week